Change of Adviser
May 17 2010 - 2:01AM
UK Regulatory
TIDMMEDG
RNS Number : 9768L
Medgenics Inc
17 May 2010
For release: 17 May 2010
Medgenics, Inc.
("Medgenics" or the "Company")
Appointment of Nomura-Code as Joint-Broker
Medgenics (LSE: MEDG, MEDU), the company that is developing a novel approach to
the manufacture and delivery of therapeutic proteins continuously in patients
using their own tissue, is proud to announce today the appointment of Nomura
Code Securities as joint-broker to the Company with SVS Securities plc with
immediate effect.
Commenting on the new appointment Dr. Andrew Pearlman, CEO of Medgenics said:
"We are delighted by this new appointment and believe that the combination of
Nomura Code Securities, with acknowledged expertise in the life sciences space
and its reputation amongst institutional investors, and SVS Securities plc, with
its small cap investor expertise, greatly strengthens Medgenics broking team to
support the Company going forward"
For further information, please contact:
Andrew Pearlman + 972 4 902 8900
CEO, Medgenics, Inc
Mike Wort / Anna Dunphy + 44 207 861 3838
De Facto Communications
Jonathan Senior +44 207 776 1219
Nomura Code
Ian Callaway / Alex Mattey +44 207 638 5600
SVS Securities
James Pinner / Derek Crowhurst +44 207 444 0800
Religare Capital Markets (Nomad)
This information is provided by RNS
The company news service from the London Stock Exchange
END
APPAIMITMBTBBLM
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From May 2024 to Jun 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2023 to Jun 2024